Recent advances in synergistic antitumor effects exploited from the inhibition of ataxia telangiectasia and rad3-related protein kinase (atr)

HIGHLIGHTS

• who: Li-Wei Wang et al. from the School of Pharmacy, Hangzhou Normal University, Hangzhou, China have published the paper: Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR), in the Journal: Molecules 2022, 2491 of /2022/
• what: The Phase I trial is designed to examine M1774 alone or in combination with niraparib in patients with metastatic or locally advanced unresectable solid tumors (clinical trial ID: NCT04170153) .
• future: The area should attract greater attention in the coming future in drug discovery. The results . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.